MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.
about
Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells.Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer.lncRNA HOTAIR Contributes to 5FU Resistance through Suppressing miR-218 and Activating NF-κB/TS Signaling in Colorectal Cancer.MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2.LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1.Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression.Long noncoding RNA MALAT1 promotes cell proliferation through suppressing miR-205 and promoting SMAD4 expression in osteosarcoma.MALAT1-miR-101-SOX9 feedback loop modulates the chemo-resistance of lung cancer cell to DDP via Wnt signaling pathway.Dihydroartemisinin inhibits EMT induced by platinum-based drugs via Akt-Snail pathway.Ginkgo biloba extract EGb 761-induced upregulation of LincRNA-p21 inhibits colorectal cancer metastasis by associating with EZH2.Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma.Long noncoding RNA TUG1 is a diagnostic factor in lung adenocarcinoma and suppresses apoptosis via epigenetic silencing of BAX.Targeting LncRNA-MALAT1 suppresses the progression of osteosarcoma by altering the expression and localization of β-catenin.From biomarkers to therapeutic targets-the promises and perils of long non-coding RNAs in cancer.LncRNA-PVT1 promotes pancreatic cancer cells proliferation and migration through acting as a molecular sponge to regulate miR-448.Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma.Silencing long noncoding RNA PVT1 inhibits tumorigenesis and cisplatin resistance of colorectal cancer.LncRNAs regulate cancer metastasis via binding to functional proteins.HIF‑1α‑induced upregulation of lncRNA UCA1 promotes cell growth in osteosarcoma by inactivating the PTEN/AKT signaling pathway.Chronic oxymatrine treatment induces resistance and epithelial‑mesenchymal transition through targeting the long non-coding RNA MALAT1 in colorectal cancer cells.Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma.Exosome-mediated transfer of lncRNA RP11‑838N2.4 promotes erlotinib resistance in non-small cell lung cancer.Identification of the tumor-suppressive function of circular RNA ITCH in glioma cells through sponging miR-214 and promoting linear ITCH expression.Energy stress-induced lncRNA HAND2-AS1 represses HIF1α-mediated energy metabolism and inhibits osteosarcoma progression.MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches.Expression of metastasis-associated lung adenocarcinoma transcript 1 long non-coding RNA in vitro and in patients with non-small cell lung cancer.A Novel Probability Model for LncRNA⁻Disease Association Prediction Based on the Naïve Bayesian Classifier.Increased MALAT1 expression contributes to cisplatin resistance in non-small cell lung cancermiRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal Cancer
P2860
Q39254523-59435E9E-C82E-428C-9D5D-64B7591C2882Q39438832-8271D5F8-9DA0-47AE-A5D5-75B7CA16F845Q41191235-DFF57CE5-C52D-4C25-9496-323EF9EB4D7EQ41470862-8A893648-3FC1-4063-BC17-6A845D089D59Q42654010-89711EFF-B7E7-49E3-AC7D-849EFFF873E3Q47106149-0BADADE9-1E7A-402F-B247-4D84A51CF4E5Q47119874-0CF66979-0A27-4DB4-AC8A-4E7BCBBE55F8Q47127087-872A91DE-C6A4-473B-9092-8B42A694D3C0Q47142435-5EDBEB56-C718-49E4-AC1F-90E4BB2C8A9CQ47146370-79C554AA-86BD-4B23-88E6-F04F95C60931Q47149175-4463915E-E050-4D61-8733-48549FD027A3Q47160990-22F4AF9F-6B76-47AC-AC02-572FB199DD63Q47162683-6FB1976B-806E-4A64-A9BF-032AE47D9945Q47287055-71440799-A451-4C7A-AA3B-982B01987E0CQ48212048-BC257F24-024A-42E2-B7B8-C24AEC16995FQ48300802-FB747B79-3FB9-4815-9952-97C6F3B3CCBFQ49286697-EAC5FFCD-6AB4-4879-95B8-ADFDC2FA7E03Q49740926-12C9E026-64B0-44FD-9533-32F77CACD05DQ50067715-7CE98E1A-CC70-4EAF-8BF4-F1CE7E591BE4Q50068000-3AEDC961-FC01-43CB-BA82-7D5B55DBE91BQ52597053-DCF9E24F-C909-4296-9AFC-F98AC2F2F604Q52685797-B5D3108A-D4BE-484E-82CE-86A2439E11D5Q54977761-BAFA8533-0FE7-44E9-867F-FF53F829CD55Q55005059-B3929BCC-6474-454F-955C-0E2042A83F15Q55026439-76C7A163-250A-427F-9773-848331333D63Q55245371-A8E36D67-7F7E-4A27-B878-093ECD5F7A72Q55286324-8EDF986C-1E57-456E-B572-8C9CC2DEB596Q55456649-E7D149BA-2AFF-4726-86FA-571E6DCF7E21Q58788865-76EC9FCF-82AC-4F20-A0E1-C0F9AAE1F554Q58799032-D0A2B4BC-9790-4FA7-8497-FD91CC9FDF62
P2860
MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
MALAT1 Is Associated with Poor ...... Chemoresistance through EZH2.
@en
type
label
MALAT1 Is Associated with Poor ...... Chemoresistance through EZH2.
@en
prefLabel
MALAT1 Is Associated with Poor ...... Chemoresistance through EZH2.
@en
P2093
P1476
MALAT1 Is Associated with Poor ...... Chemoresistance through EZH2.
@en
P2093
Chuanxin Wang
Haiyan Wang
Peilong Li
Yongmei Yang
P304
P356
10.1158/1535-7163.MCT-16-0591
P577
2017-01-09T00:00:00Z